Abstract: A method of making an acrylate monomer from an essentially ethoxylated polyol, which monomer has a reduced and very low Primary Irritation Index (PII value). The base polyol is di, tri, tetra or polyhydroxyfunctional and the reduced PII value is obtained by reducing the formation of by-products such as monoethylene, diethylene and triethylene glycol during the ethoxylation of the base polyol. A polyol is reacted with propylene oxide at a molar ratio of 1:0.5-1:2.5 and in the presence of an alkali metal hydroxide catalyst. The polyol propoxylate obtained is reacted with ethylene oxide at a molar ratio of 1:2-1:10, whereby an ethoxylated polyol propoxylate with an average molecular weight of 270-500 is obtained. The ethoxylated polyol propoxylate is finally acrylated to yield an acrylate monomer having at least one acrylic unsaturation.

Abstract: A process of lubricating or releasing comprising disposing a lubricant release composition between frictional contacting parts or between parts to be released from each other, respectively, wherein the composition includes 5-alkyl-1,3-dioxane-5-methanol and esters and/or ethers thereof, the alkyl in the aforementioned compounds being methyl or ethyl.

Abstract: Storage container, preferably a storage tray (1) of plastic having detachable partition walls (2), the container being provided with opposite vertical recesses or pairs of vertical ledges (5) along the inner side of the two long sides (3, 4). The container (1) comprises an inwards directed horizontal ledge (6) at the top along the inner side of each of the two long sides (3, 4), locking means (7) arranged in the upper edge of the ledges (6) on the two long sides (3, 4) of the container (1) in connection with each recess or pair of ledges (5), partition walls (2) including a lower part (8) and an upper part (9) connected to each other by an integrated hinge (10), whereby the parts (8, 9 and 10) are made of plastic in one piece, the upper part (9) being provided with locking means (11) along each short side which locking means (1 1) arc intended to co-operate with the locking means (7) on the container (1).

Abstract: The invention relates to a dendritic macromolecule of the polyester type comprising a central initiator molecule or initiator polymer having one or more reactive hydroxyl groups (A). The groups (A) are under formation of an initial tree structure bonded to reactive carboxyl groups (B) of a monomeric chain extender having the two reactive groups (A) and (B). The tree structure is optionally extended and further branched from the initiator molecule or initiator polymer by addition of further molecules of a monomeric chain extender by means of bonding between the reactive groups (A) and (B) thereof and is thereafter optionally further extended by reaction with a chain stopper. The invention also comprises a process for preparation of the dendritic macromolecule.

Abstract: A method of preventing or alleviating pain by administering to a human or other mammal in need thereof of a pain preventing or alleviating effective amount of a pharmaceutical composition comprising at least one specific isomer of inositol triphosphate.

Abstract: The invention relates to a flowability improving agent comprising a combination, calculated on a dry product, of: A) 60-99% by weight of a sulphonated melamine-formaldehyde resin, a sulphonated melamine-urea-formaldehyde resin or a sulphonated naphthalene-formaldehyde resin; C) 0.5-40% by weight of a boron containing polyhydroxycarboxylic acid or a water-soluble salt of such an acid and optionally D) 0.5-30% by weight of a compound with formulaAr O--(R.sub.1).sub.n --R.sub.2where Ar is unsubstituted or substituted benzene moiety or naphthalene moiety, R.sub.1 is an oxyethylene group; --CH.sub.2 CH.sub.2 O--or an oxypropylene group; ##STR1## an oxyethylene chain or an oxypropylene chain with up to fifteen oxyethylene groups or oxypropylene groups or a combination of oxyethylene groups and oxypropylene groups to a chain where the sum of these groups is at most fifteen; the mean value n for n is 1-15 and R.sub.2 is hydrogen or a phosphonate group with the formula ##STR2## where M.sub.1 and M.sub.

Abstract: A method of preventing or alleviating tissue damage, diabetes and complications thereof, bone disorders, disorders related to transplantation, disorders related to abnormal levels of lipoproteins, cardiovascular disease and inflammatory disorders by providing a mammal having one or more of the above diseases with a preventing or an alleviating effective amount of a compound having the formula C.sub.6 H.sub.6 (OH).sub.6-n (OPO.sub.3 H.sub.2).sub.n, where n is an integer of 1 or 2.

Abstract: A method of preventing or alleviating renal disorders by administering to a human or an animal in need thereof a pharmaceutical composition comprising an effective amount amount of at least one specific isomer of inositol trisphosphate sufficient to obtain said prevention or alleviation.

Abstract: Process for the production of di-trimethylolpropane (di-TMP), which comprises subjecting a solution containing less than 3 per cent by weight, preferably less than 1 per cent by weight of water, free trimethylolpropane (TMP) and/or partial ester between TMP and a monocarboxylic acid or its anhydride having 1-4 carbon atoms in the chain, which partial ester on average contains 1.0-2.5, preferably 1.0-2.0 ester groups per molecule to an etherification reaction by heating to 50.degree.-200.degree. C., preferably 70.degree.-190.degree. C. in the presence of an acid catalyst in solid state or in dissolved state until at most 30%, preferably at most 15% of the total content of free TMP and partial ester of TMP in the solution has been etherified to free di-TMP and partial ester of di-TMP respectively, at the same time continuously removing etherification water formed at the etherification reaction under vacuum at a pressure of 0.1-200 mm Hg, preferably 0.

Abstract: The present invention relates to the use of inositoltrisphosphate (IP.sub.3) for the preparing of a medicament effective as a neuropeptide Y- (NPY-) antagonist and to a pharmaceutical composition comprising at least one specific isomer of IP.sub.3 and a pharmaceutically active compound effective in the cardiovascular, renal and/or cerebral area.

Abstract: New derivatives of cyclohexane in substantially pure form suitable as pharmaceutical, foodstuff or as a stabilizer.

Abstract: New derivatives of cyclohexane in substantially pure form suitable as a pharmaceutical, foodstuff or as a stabilizer.

Abstract: Inositol phosphates and/or derivatives thereof are analytically separated, whereby a quaternary amine is mixed with an aqueous solution containing one or more inositol phosphates and/or derivatives thereof. The aqueous solution obtained is fed to an analytical column containing a solid non-polar phase and the different constituents thereof are detected.

Abstract: New derivatives of cyclohexane in substantially pure form suitable as a pharmaceutical, foodstuff or as a stabilizer.

Abstract: A method of reducing the negative effect of cadmium or aluminum ion or free-radicals in body tissues and a method of alleviating cardiovascular diseases and conditions by administering to a human or an animal a pharmaceutical composition comprising an amount of at least one specific isomer of inositol triphosphate sufficient to obtain said alleviation.

Abstract: A method of preventing or alleviating certain conditions by administering to a human or an animal a pharmaceutical composition comprising an amount of at least one specific isomer of inositol trisphosphate sufficient to obtain said prevention or alleviation.